Biota Pharmaceuticals’ (AVIR) “Buy” Rating Reiterated at HC Wainwright
Separately, FBR & Co reissued an outperform rating on shares of Biota Pharmaceuticals in a research note on Tuesday, May 31st. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus target price of $5.50.
Shares of Biota Pharmaceuticals (NASDAQ:AVIR) opened at 1.68 on Tuesday. The firm has a 50-day moving average price of $1.40 and a 200-day moving average price of $1.47. The firm’s market cap is $64.92 million. Biota Pharmaceuticals has a 12-month low of $1.23 and a 12-month high of $2.31.
Biota Pharmaceuticals (NASDAQ:AVIR) last posted its earnings results on Wednesday, September 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by $0.43. Biota Pharmaceuticals had a negative net margin of 272.04% and a negative return on equity of 46.02%. Equities research analysts anticipate that Biota Pharmaceuticals will post ($0.85) EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Gabelli Securities Inc. purchased a new position in Biota Pharmaceuticals during the second quarter valued at $314,000. BVF Inc. IL bought a new stake in Biota Pharmaceuticals during the second quarter valued at about $292,000. California Public Employees Retirement System bought a new stake in Biota Pharmaceuticals during the second quarter valued at about $139,000. Towerview LLC bought a new stake in Biota Pharmaceuticals during the second quarter valued at about $224,000. Finally, Eagle Global Advisors LLC bought a new stake in Biota Pharmaceuticals during the second quarter valued at about $381,000. 34.53% of the stock is owned by institutional investors.
About Biota Pharmaceuticals
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.
Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.